FGF2 and hepatocellular carcinoma: As previously discussed, an anti-FGF2 diabody could represent a potential therapeutic agent for the inhibition of metastasis formation and immune escape because it was able to inhibit the anti-PD-L1 expression and EMT in hepatoma cells [22].